Non-Current Assets
AFS Securities
Moderna AFS Securities decreased by 3.6% to $2.25B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.9%, from $2.42B to $2.25B. Over 5 years (FY 2020 to FY 2025), AFS Securities shows an upward trend with a 29.6% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2017
Last reportedQ1 2026May 1, 2026
Parent metricTotal investment securities
How to read this metric
Changes reflect the company's long-term investment strategy and the market valuation of its non-core asset portfolio.
Detailed definition
These are debt or equity investments that are not classified as trading or held-to-maturity, recorded at fair value on t...
Peer comparison
Common among large-cap biotech and pharmaceutical firms with significant cash reserves looking for long-term yield.
Metric ID:
fin_afs_securitiesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.21B | $6.44B | $6.84B | $9.17B | $10.16B | $8.66B | $8.32B | $7.44B | $6.11B | $5.27B | $4.68B | $3.64B | $2.33B | $2.34B | $2.49B | $2.42B | $2.37B | $2.14B | $2.34B | $2.25B |
| QoQ Change | — | +53.1% | +6.2% | +34.0% | +10.8% | -14.8% | -3.9% | -10.5% | -18.0% | -13.6% | -11.3% | -22.2% | -36.1% | +0.4% | +6.8% | -3.0% | -1.8% | -9.7% | +9.0% | -3.6% |
| YoY Change | — | — | — | — | +141.5% | +34.4% | +21.6% | -18.9% | -39.9% | -39.1% | -43.8% | -51.1% | -61.9% | -55.7% | -46.7% | -33.5% | +2.1% | -8.2% | -6.3% | -6.9% |
Range$2.14B – $10.16B
CAGR-12.3%
Avg YoY Growth-13.3%
Median YoY Growth-26.2%
AFS Securities at Other Companies
Frequently Asked Questions
- What is Moderna's afs securities?
- Moderna (MRNA) reported afs securities of $2.25B in Q1 2026.
- How has Moderna's afs securities changed year-over-year?
- Moderna's afs securities decreased by 6.9% year-over-year, from $2.42B to $2.25B.
- What is the long-term trend for Moderna's afs securities?
- Over 5 years (2020 to 2025), Moderna's afs securities has grown at a 29.6% compound annual growth rate (CAGR), from $639M to $2.34B.
- What does afs securities mean?
- Long-term investments in securities that are held for potential future sale or income.